PMID- 16391369 OWN - NLM STAT- MEDLINE DCOM- 20060112 LR - 20071115 IS - 1460-2105 (Electronic) IS - 0027-8874 (Linking) VI - 98 IP - 1 DP - 2006 Jan 4 TI - Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. PG - 26-38 AB - BACKGROUND: Postmastectomy radiation therapy reduces locoregional recurrence among women with operable breast cancer, but whether it improves survival has been controversial. We reanalyzed the results from 36 unconfounded trials (i.e., addition of radiation therapy was the sole discriminant between treatments being compared) that were identified in previous meta-analyses, which provided 38 comparisons. METHODS: We used three predefined treatment categories for individual patient data: 1) a biologically equivalent dose (BED) of 40-60 Gy in 2-Gy fractions with an appropriate target volume, 2) an inadequate or excessive dose of radiation therapy, and 3) an inappropriate target volume. Effects of radiation therapy on 5-year and 10-year survival in each of the treatment categories were estimated from a cohort of 13 199 patients from the published rates or, if these were unavailable, from the published survival curves. We also used this categorization to reanalyze data from Early Breast Cancer Trialists' Collaborative Group (EBCTCG) postmastectomy studies. At 10 years, 16 (84%) of the 19 comparisons in our study coincided with those reported by the EBCTCG. All statistical tests were two-sided. RESULTS: Twenty-five of the 38 available comparisons had used optimal and complete radiotherapy (i.e., category 1). Of these 25 comparisons, 17 had 5-year data, and these data showed that adjuvant radiation therapy was associated with a 2.9% absolute increase in survival (odds ratio [OR] of death = 0.87, 95% confidence interval [CI] = 0.79 to 0.96; P = .006). Thirteen category 1 trials had data at 10 years, and these data showed that adjuvant radiation therapy was associated with a statistically significant 6.4% absolute increase in survival (OR of death = 0.78, 95% CI = 0.70 to 0.85; P < .001). No statistically significant change in survival was observed among category 2 (OR of death = 0.91, 95% CI = 0.75 to 1.11) or 3 (OR of death = 0.97, 95% CI = 0.61 to 1.55) trials. Among the 33 EBCTCG studies, odds of local recurrence were reduced more among category 1 trials (80% lower) than among category 2 (70% lower) or 3 (64% lower) trials (P(heterogeneity) < .001). Odds of all-cause death were also lower among category 1 trials (13% lower) than among category 2 (3% lower) or 3 (26% higher) trials (P(heterogeneity) = .01). CONCLUSIONS: Adjuvant radiation therapy with an optimal BED and target volume was statistically significantly associated with improved survival for up to 10 years. FAU - Gebski, Val AU - Gebski V AD - National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Australia. val@ctc.usyd.edu.au FAU - Lagleva, Marivic AU - Lagleva M FAU - Keech, Anthony AU - Keech A FAU - Simes, John AU - Simes J FAU - Langlands, Allan O AU - Langlands AO LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PL - United States TA - J Natl Cancer Inst JT - Journal of the National Cancer Institute JID - 7503089 SB - IM EIN - J Natl Cancer Inst. 2006 Jun 21;98(12):876 CIN - J Natl Cancer Inst. 2006 Jan 4;98(1):3-4. PMID: 16391361 CIN - J Natl Cancer Inst. 2006 Jul 19;98(14):1020-1; author reply 1021-2. PMID: 16849687 CIN - J Natl Cancer Inst. 2006 Jul 19;98(14):1021; author reply 1021-2. PMID: 16849688 MH - Breast Neoplasms/*mortality/pathology/*radiotherapy/surgery MH - Confidence Intervals MH - Disease-Free Survival MH - Female MH - Humans MH - *Mastectomy MH - Multicenter Studies as Topic MH - Neoplasm Recurrence, Local/prevention & control MH - Neoplasm Staging MH - Odds Ratio MH - Radiotherapy Dosage MH - Radiotherapy Planning, Computer-Assisted MH - Radiotherapy, Adjuvant/*methods MH - Randomized Controlled Trials as Topic MH - Survival Analysis MH - Therapeutic Equivalency MH - Time Factors MH - Treatment Outcome EDAT- 2006/01/05 09:00 MHDA- 2006/01/13 09:00 CRDT- 2006/01/05 09:00 PHST- 2006/01/05 09:00 [pubmed] PHST- 2006/01/13 09:00 [medline] PHST- 2006/01/05 09:00 [entrez] AID - 98/1/26 [pii] AID - 10.1093/jnci/djj002 [doi] PST - ppublish SO - J Natl Cancer Inst. 2006 Jan 4;98(1):26-38. doi: 10.1093/jnci/djj002.